Physician profile
Gregory A Smith
NPI 1245204890
$3,646.88
in general payments reported to CMS, 2019-2025
24 companies · $657 in 2025
The $657 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $851 · 2022: $890 · 2023: $825 · 2024: $423 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $740.82 | 2021-2025 | |
| Novo Nordisk INC | $724.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $574.06 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $221.98 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $215.88 | 2021-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $154.36 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $134.52 | 2021-2025 | Nexletol |
| Getinge USA Sales, LLC | $124.24 | 2023 | Vasoview Hemopro 2 |
| Corcept Therapeutics | $102.33 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $85.30 | 2023-2025 | Inspire |
| Abbott Laboratories | $82.66 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $75.22 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.52 | 2022-2025 | Jardiance |
| Amgen INC. | $67.14 | 2023-2025 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $54.25 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $38.50 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $36.01 | 2024-2025 | Voquezna |
| Itamar Medical INC | $28.27 | 2023 | Watchpatone |
| Glaxosmithkline, LLC. | $23.55 | 2022 | |
| Baxter Healthcare | $23.42 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $21.00 | 2023 | Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $19.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2021 | |
| Optos, INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.